GlassScriptPhysician profile
Munir Ahmad
NPI 1881618957
$3,499.14
in general payments reported to CMS, 2019-2025
37 companies · $959 in 2025
The $959 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $159 · 2021: $326 · 2022: $123 · 2023: $582 · 2024: $921 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,219 · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,219.38 |
| Education | $243.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $325.10 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $276.44 | 2019-2025 | Imfinzi, Imjudo |
| Amgen INC. | $223.05 | 2019-2021 | |
| Pfizer INC. | $214.57 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $209.61 | 2021-2023 | Imbruvica, Epkinly |
| Glaxosmithkline, LLC. | $207.81 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Seagen INC. | $202.51 | 2021-2023 | Adcetris |
| Daiichi Sankyo INC. | $201.49 | 2024-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $194.29 | 2019-2021 | |
| Abbvie INC. | $172.78 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $129.87 | 2019-2021 | |
| Kite Pharma, INC. | $126.56 | 2020-2025 | Yescarta |
| Celgene Corporation | $118.97 | 2024 | Pomalyst |
| Alexion Pharmaceuticals, INC. | $99.00 | 2019 | |
| Merck Sharp & Dohme LLC | $80.48 | 2025 | Keytruda, Welireg, Lynparza |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munir Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.